Affiliations 

  • 1 Department of Haematology, Ampang Hospital, Jalan Mewah Utara, Pandan Mewah, 68000 Ampang, Selangor Malaysia
  • 2 2Clinical Trial Unit, Clinical Research Centre, Ministry of Health, Ampang, Selangor Malaysia
  • 3 Department of Haematology, Penang General Hospital, George Town, Penang Malaysia
  • 4 4Department of Haematology, Hospital Sultanah Aminah, Johor Bahru, Johor Malaysia
  • 5 Department of Haematology, Ipoh Hospital, Ipoh, Perak Malaysia
  • 6 Department of Haematology, Melaka Hospital, Melaka City, Melaka Malaysia
  • 7 7Department of Haematology, Hospital Universiti Sains Malaysia, Kota Bharu, Kelantan Malaysia
  • 8 8Department of Haematology, Queen Elizabeth Hospital, Kota Kinabalu, Sabah Malaysia
  • 9 9Department of Haematology, Sarawak General Hospital, Kuching, Sarawak Malaysia
  • 10 10Department of Haematology, Hospital Raja Perempuan Zainab II Kota Bahru, Kota Bahru, Kelantan Malaysia
  • 11 Department of Haematology, Ampang Putri Hospital, Ampang, Selangor Malaysia
  • 12 Department of Haematology, Gleneagles Penang Hospital, George Town, Penang Malaysia
  • 13 13Department of Haematology, Taiping Hospital, Taiping, Perak Malaysia
  • 14 Department of Haematology, Sunway Medical Centre, Kuala Lumpur, Malaysia
Exp Hematol Oncol, 2018;7:31.
PMID: 30564475 DOI: 10.1186/s40164-018-0124-7

Abstract

Background: The evolution of molecular studies in myeloproliferative neoplasms (MPN) has enlightened us the understanding of this complex disease consisting of polycythaemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF). The epidemiology is well described in the western world but not in Asian countries like Malaysia.

Materials and methods: This retrospective national registry of MPN was conducted from year 2009 to 2015 in Malaysia.

Results: A total of 1010 patients were registered over a period of 5 years. The mean age was 54 years with male predominance. The ethnic distribution revealed that Chinese had a relatively high weighted incidence proportion (43.2%), followed by Indian (23.8%), Malay (15.8%) and other ethnic groups (17.2%). The types of MPN reported were 40.4% of ET (n = 408), 38.1% of PV (n = 385), 9.2% of PMF (n = 93), 3.1% of hypereosinophilic syndrome (HES) (n = 31) and 7.9% of unclassifiable MPN (MPN-U) (n = 80). Splenomegaly was only palpable clinically in 32.2% of patients. The positive JAK2 V617F mutation was present in 644 patients with 46.6% in PV, 36.0% in ET, 9.0% in PMF, and 7.4% in MPN-U, and had significantly lower haemoglobin (p 

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.